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Abstract
Background: Obesity is a strong predictor of poor prognosis in breast cancer, especially in postmenopausal
women. In particular, tumors in obese patients tend to seed more distant metastases, although the biology
behind this observation remains poorly understood.
Methods: To elucidate the effects of the obese microenvironment on metastatic spread, we ovariectomized C57BL/
6 J female mice and fed them either a regular diet (RD) or a high-fat diet (HFD) to generate a postmenopausal diet-
induced obesity model. We then studied tumor progression to metastasis of Py230 and EO771 grafts. We analyzed
and phenotyped the RD and HFD tumors and the surrounding adipose tissue by flow cytometry, qPCR,
immunohistochemistry (IHC) and western blot. The influence of the microenvironment on tumor cells was assessed by
performing cross-transplantation of RD and HFD tumor cells into other RD and HFD mice. The results were analyzed
using the unpaired Student t test when comparing two variables, otherwise we used one-way or two-way analysis of
variance. The relationship between two variables was calculated using correlation coefficients.
Results: Our results show that tumors in obese mice grow faster, are also less vascularized, more hypoxic, of higher
grade and enriched in CD11b+Ly6G+ neutrophils. Collectively, this favors induction of the epithelial-to-mesenchymal
transition and progression to claudin-low breast cancer, a subtype of triple-negative breast cancer that is enriched in
cancer stem cells. Interestingly, transplanting HFD-derived tumor cells in RD mice transfers enhanced tumor growth
and lung metastasis formation.
Conclusions: These data indicate that a pro-metastatic effect of obesity is acquired by the tumor cells in the primary
tumor independently of the microenvironment of the secondary site.
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Background
Obesity affects more than half a billion adults worldwide
and is a well-known risk factor for many cancers, includ-
ing breast cancer [1], showing correlation with both in-
creased risk and poor prognosis [2]. Of note, this
association is mainly linked to postmenopausal patients,
whereas in premenopausal women increased BMI corre-
lates with decreased breast cancer risk - yet more ag-
gressive progression and resistance to therapy [3].
However, the biology behind these links remains unclear,
in part due to the wide range of conditions associated
with obesity.
Obesity-derived systemic complications, including but
not restricted to inflammation, insulin resistance and
hyperglycemia have been explored as potential causative
effects or contributors to increased breast cancer risk and
progression, albeit with mixed results [4]. Obesity is com-
monly characterized by macrophage-induced chronic in-
flammation in the adipose tissue [5, 6]. The effector cells
leading to adipose tissue inflammation are M1 macro-
phages [7], which are initially recruited by T cells as
monocytes [8]. Macrophages proliferate locally in the adi-
pose tissue, a process that results in local and systemic
subclinical inflammation leading to insulin resistance, dia-
betes and further increased adiposity [9]. Recent studies
suggest that macrophages promote tumor progression in
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obesity through interactions with adipocytes [10], although
M1 macrophages typically play protective roles in tumor
formation [11]. Still, none of these studies provide
experimental evidence to explain why obesity correlates
with increased risk of distant metastasis, particularly in
postmenopausal women [12]. Recently, two groups have
found obesity to promote metastasis by two independent
tumor cell extrinsic mechanisms [13, 14]. However, we and
others have previously shown that metastasis relies on both
tumor cell extrinsic and intrinsic factors [15]. With the aim
to understand the molecular mechanisms linking obesity
and poor prognosis in postmenopausal breast cancer, we
generated a syngeneic orthotopic mouse model of post-
menopausal breast cancer and investigated the effects of
obesity on primary tumor growth and spontaneous meta-
static progression. Our results reveal a novel mechanism in-
volving hypoxia and neutrophil granulocytes-tumor cell
interactions in the primary tumor that leads to the expan-
sion of metastasis-initiating cells collectively resulting in in-
creased distant metastasis formation.
Methods
Mouse work
C57BL/6 J, FVB/N, MMTV-PyMT (FVB/N) [16], and
B6(Cg)-Rag2tm1.1Cgn/J (Rag2−/−) [17] mice were housed
in ventilated cages in the mouse husbandry of the Uni-
versity of Fribourg. For tumor cell grafting, cells were
trypsinized, resuspended in complete medium and cen-
trifuged at 1300 rpm. They were washed twice in PBS,
counted and resuspended in 1:3 Matrigel:PBS for injec-
tion into the 4th mammary fat pad. To mimic postmeno-
pausal estrogen decrease, 5–7-week-old female mice
were ovariectomized and 2 weeks later they were sup-
plied with either a high-fat diet (HFD) or a normal
(regular) diet (RD (60% and 10% fat content, respect-
ively). Mice were treated with clodronate liposomes as
previously descrived [18]. All the experiments were per-
formed by trained researchers holding the necessary ac-
creditations and in accordance to the Swiss Animal
Welfare Regulations and approved by the Cantonal Vet-
erinary Service of the Canton Fribourg (2015_07_FR).
Antibodies and reagents
The following antibodies and reagents were used:
TER119, CD3 (17A2), CD4 (GK1.5), CD8a (53–6.7),
CD19 (6D5), CD31 (MEC13.3), CD45 (30-F11), Ly6C
(HK1.4), Ly6G (RB6-8C5), CD11b (M1/70) (Biolegend),
CD31, PCNA (Santa Cruz Technologies), Cytokeratin 14
(Covance), CD11b, CD31, Ki67 (Abcam), α-SMA,
β-Tubulin, β-Actin (Sigma), Vimentin (Lifespan Biosci-
ences), N-Cadherin, E-cadherin, p21, p53 (Cell Signal-
ing), hypoxia inducible factor 1 alpha (HIF1α) (Novus
Biologicals) and PIMO (Hypoxiprobes).
Cell culture
EO771 [19] and Py230 [20] cell lines were obtained from
the American Type Culture Collection (ATCC) and
grown as recommended. Mouse tumor tissue was disso-
ciated using a mixture of Liberase TH (Roche) and
DNAse at 37 °C for 45 min. Cells were filtered, washed
twice in 2 mM EDTA in PBS and twice in PBS and then
seeded for culture.
Fluorescence-activated cell sorting (FACS) analysis
For FACS analysis, tumor cells derived from tumor
grafts (Py230 and EO771) or primary MMTV-PyMT tu-
mors were obtained by disaggregating the tumors with
Liberase TH (Roche) and DNAse at 37 °C for 45 min
with agitation. Cells were then washed, filtered, stained
with the appropriate antibodies for 30 min at 4 °C;
4',6-diamidino-2-phenylindole (DAPI) was used to stain
and discard dead cells. Fluorescence was analyzed using
a MACSQuant (Miltenyi) analyzer. FACS data were
processed and analyzed using FlowJo.
Immunohistofluorescence
Immunostaining was performed on 4-μm-thick paraffin
sections. Antigen retrieval was induced by heating the
samples to 95 °C for 30 min in citrate buffer, pH 6.0.
After blocking, we incubated the sections with the indi-
cated antibodies overnight at 4 °C, and then used the
secondary fluorescently labeled antibodies Alexa Fluor
488, 567 and 647 (Molecular Probes, Invitrogen) or
HRP-conjugated secondary antibodies (Dako). Fluores-
cent images were taken with a TCS-SP5 confocal micro-
scope (Leica). Light images were taken with a widefield
microscope (Leica).
Western blot
Protein was extracted with complete radioimmunopreci-
pitation assay (RIPA) buffer, separated by electrophor-
esis, transferred to polyvinylidene fluoride (PVDF)
membranes, blocked with 5% BSA and incubated over-
night with primary antibodies. Immunoreactive bands
were visualized using HRP-conjugated secondary anti-
bodies (Cell Signaling).
Real-time PCR
RNA was prepared using the mini RNeasy kit (Qiagen).
Complementary DNAs (cDNAs) were generated using
oligo-T priming and the M-MLV transcriptase (H-)
point mutant (Promega) and quantitative PCR (qPCR)
was performed in a StepOnePlus thermocycler (Applied
Biosystems) using the SYBR green PCR Master Mix
(Kapa). A list of the primers used is shown in Additional
file 1: TableS1.
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Statistics
Data were analyzed using GraphPad Prism 6. Means were
compared using the unpaired Student t test. Samples were
analyzed using Mann-Whitney’s non-parametric test if the
data were not normally distributed (with normality assessed
using the D’Agostino-Pearson omnibus normality test).
When comparing more than two variables, we performed
one-way or two-way analysis of variance (ANOVA). To iso-
late differences between groups in ANOVA, we performed
Fisher’s least significant difference (LSD) test. We tested cor-
relation using Pearson’s correlation coefficient or Spearman’s
nonparametric correlation analysis depending on the data
distribution. The p values are indicated for each experiment.
Error bars in the figures indicate standard deviation unless
stated otherwise in the figure legends. Significant differences
between experimental groups are indicated with asterisks as
follows: *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001.
Results
Mice fed with a HFD experience faster tumor growth and
progression to metastasis
In order to recapitulate postmenopausal obesity and as-
sess how it affects breast cancer progression, we first
generated an experimental model following the strategy
schematically depicted in Additional file 2: Figure S1A.
Ovariectomizing C57BL/6 J mice and feeding them with a
high-fat diet (HFD, 60% fat content) significantly increased
weight gain compared to non-ovariectomized HFD-fed
mice and ovariectomized or non-ovariectomized mice fed
with a regular diet (RD) (Additional file 2: Figure S1B). Be-
tween 20 and 25 weeks of age, the difference between the
mean of the final weight in both groups was 39.7%
(Additional file 2: Figure S1C). In addition, obese mice de-
veloped the common systemic conditions frequently ob-
served in the HFD mouse model, such as hyperinsulinemia
(data not shown) [21]. Obesity is mainly associated with es-
trogen receptor alpha-positive (ERα+) breast tumors [22].
To mimic human disease, we next performed syngeneic
transplants in the mammary fat pad of C57BL/6 J mice
with two different murine breast cancer cell lines that are
hormone-sensitive in vivo, EO771 and Py230 [23, 24], and
studied primary tumor growth and progression. As shown
in Fig. 1a and b, E0771 and Py230 tumors in the HFD
group grew significantly bigger. As with humans, in rodents
the susceptibility to gain weight in response to obesogenic
diets differs substantially between individuals [25, 26]. This
variability is reflected within our experimental groups, since
neither the RD nor the HFD body weights follow a
normal distribution but are negatively and positively
skewed, respectively (p < 0.0068; n = 29 and p < 0.007;
n = 35, Additional file 2: Figure S1D and E). Neverthe-
less, our analyses revealed that body weight moder-
ately correlated with tumor mass (Fig. 1c), which is
again in agreement with observations in humans [27].
Interestingly, metastasis was also significantly in-
creased in obese mice (Fig. 1d, e), even when there
was no significant correlation between the size of the
tumor and the number of metastatic foci in our con-
trol groups (r = 0.29, p = 0,22). Comparing same-sized
tumors rendered similar results (Additional file 2:
Figure S1F and G). To understand whether this in-
crease in metastasis was due to tumor or host derived
factors, we injected Celltracker-labeled Py230 cells
into the tail vein of lean and obese mice and studied
lung colonization using FACS after 2 h, as the time
point for initial tumor cell trapping/seeding, and after
48 h, when most cells have extravasated. Our results
show that there are no major differences in initial
seeding and extravasation in lean compared to obese
mice (Fig. 1f ). Furthermore, we did not observe sig-
nificant differences in the number of metastatic colonies
formed upon tail vein injection, though there was a slight,
non-significant trend toward more metastasis formation
in obese mice (Fig. 1g, h). Taken together, these results
demonstrated that obesity in ovariectomized mice pro-
motes the formation of larger tumors and increased lung
metastasis formation in the two models tested.
Obesity and not dietary factors is responsible for
differences in tumor progression
Recent clinical data suggest that a diet rich in unsat-
urated fatty acids correlates with breast cancer risk
independently of body mass index (BMI) [28], par-
ticularly in postmenopausal women [29]. However, it
is still not clear whether the diet itself contributes to
a poor prognosis in those patients with breast cancer
or whether obesity is required. We then aimed at
assessing whether the effects observed on tumor
growth and metastasis in our model were due to
obesity or to the diet. It is well-known that alterna-
tively activated macrophages (M2) protect against
obesity and insulin resistance [30]. We therefore rea-
soned that using M1/Th1 and M2/Th2-biased mouse
strains [31] would allow us to discriminate the rele-
vance of the diet versus obesity in our setting.
Hence, we switched to the FVB/N mouse strain, an
archetypical M2/Th2-biased mouse strain, in which
we could use the PyMT tumor model for consistency
purposes. We ovariectomized female mice, fed them
with either a RD or HFD and performed syngeneic
transplants with MMTV-PyMT tumor-derived cells.
Our results show that FVB/N mice did not gain
weight after 12 weeks on the HFD regimen (Fig. 2a).
Contrary to Py230-injected C57BL/6 mice, in which
RD and HFD tumor growth rates diverge very early
(Fig. 2b), we found that FVB/N mice, tumors did not
differ in growth kinetics between the RD and HFD
groups (Fig. 2c). Recruitment and activation of resting
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macrophages into proinflammatory ones in the adi-
pose tissue requires previous infiltration by CD8+ ef-
fector T cells [8]. Therefore, we argued that the
absence of lymphocytes in an M1/Th1 biased strain
should be sufficient to prevent obesity and rescue the
obesity-mediated effects on tumor growth depicted in Fig. 1.
Indeed, our results demonstrate that C57BL/6 J Rag2−/−
mice, which lack T and B cells but not macrophages, did
not become obese after 12 weeks of HFD (Fig. 2d).
Consistent with the lack of T cells, overall tumor
growth was faster in C57BL/6 Rag2−/− mice than in
FVB/N mice. However, Py230 tumors did not pro-
gress faster in C57BL/6 Rag2−/− mice fed with HFD
compared to RD controls (Fig. 2e). Moreover, in
contrast to HFD-fed wild-type C57BL/6 J controls,
the peritumoral adipose tissue of HFD-fed FVB/N
mice had fewer crown-like structures - histologic
arrangements composed of macrophages and dead or
dying adipocytes that define white adipose tissue in-
flammation (Fig. 2f ) [32]. Likewise, the peritumoral
adipose tissue of obese wild-type C57BL/6 J mice
had higher expression of monocyte chemoattractants
such as Ccl2 (Fig. 2g), which is in agreement with
human data [5]. Overall, these results indicate that
in our experimental model, obesity promotes primary
tumor growth and metastasis formation, while HFD
in the absence of obesity is not sufficient to do this.
Obesity reduces angiogenesis and promotes hypoxia in
the primary site
We then aimed at investigating possible reasons for fas-
ter primary tumor progression in obese mice. Not sur-
prisingly, we observed an increase in the fraction of
proliferating cancer cells in early-stage tumors in obese
Fig. 1 Effects of a high-fat diet (HFD) on tumor progression in mice. The tumor weight is increased in the HFD groups in both EO771 grafts (a,
n = 14 regular diet (RD) and n = 16 HFD) and Py230 grafts (b, n = 11 RD and n = 15 HFD). Tumor weight correlates with body weight (c, N = 60).
The number of lung metastases is increased in both EO771 tumor-bearing mice (d, n = 14 RD and n = 16 HFD) and Py230 bearing mice (e; n = 19
sections, RD and n = 61 sections, HFD). Py230 cells have the same extravasation capabilities in both obese and lean mice as seen by the percentage
of Celltracker-labeled cells in the lungs at 2 h (n = 3 RD and n = 3 HFD) and 48 h (n = 4 RD and n = 4 HFD) by FACS (f). The number of metastatic
colonies is also not changed in the RD compared to the HFD groups in Py230 (g, n = 4) or E0771 (h, N = 11)
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mice (Fig. 3a). To study the association between obesity
and faster tumor progression, we next analyzed tumor
angiogenesis. A number of reports show that in obesity,
angiogenesis cannot cope with adipose tissue growth
[33–37]. We hypothesized that this might be mirrored in
tumors, since the mammary gland is mainly composed
of adipose tissue and tumors are surrounded by and in
close contact with adipose tissue. In agreement with
this, we found fewer vessels and lower fractions of
CD31+ cells in tumors in obese mice (Fig. 3b, c and
Additional file 2: Figure S2A). To understand the impact
of decreased angiogenesis on oxygen levels in tumors in
HFD-fed mice, we injected mice with pimonidazole and
found higher hypoxic regions in tumors in obese mice
(Fig. 3d). Furthermore, hypoxia in tumors from obese
mice led to the accumulation of HIF1α (Additional file 3:
Figure S2B), which consequently activated the transcription
of specific hypoxia-target genes (Fig. 3e). Interestingly,
HIF1α is known to be highly activated in triple-negative
breast cancer (TNBC) [38, 39], a subset of aggressive breast
cancers most of which are high-grade and present a high
risk of metastasis and recurrence [40]. Indeed, histological
analyses revealed that in obese mice the tumor mass
was less differentiated, more often lacking glandular
structures and possessing bigger nuclei (Additional file 3:
Figure S2C). In addition, Py230 tumors in obese mice
showed a consistent reduction in ERα, human epider-
mal growth factor receptor 2 (HER2), GATA3 and cyto-
keratin 18 and a gain in vimentin and c-Myc expression
(Fig. 3f and Additional file 3: Figure S2D), suggestive of
differentiation into more aggressive TNBC tumors.
Overall, our results indicate that obesity causes reduced
angiogenesis and triggers hypoxia in primary tumors,
which promotes tumor progression.
Fig. 2 Obesity and not a high-fat diet (HFD) is responsible for tumor progression. FVB/N mice do not gain weight after 13 weeks of HFD (a, n = 4
regular diet (RD) and n = 5 HFD). Py230 tumors in C57BL/6 mice grow significantly faster in obese mice (b, n = 40), while in FVB/N mice PyMT
tumors do not differ in growth dynamics between the RD and HFD groups (c, n = 4). C57BL/6 Rag2−/− mice do not gain weight on a HFD (d,
n = 4 RD and n = 5 HFD), nor do Py230 tumors differ significantly in their growth dynamics when grafted in C57BL/6 Rag2−/− mice (e, n = 4 RD
and n = 5 HFD). Immunohistochemical analysis of CD11b in the adipose tissue of RD and HFD C57BL/6 mice (scalebar 50 um) and quantification
of crown-like structures in C57BL/6, FVB/N and C57BL/6 Rag2−/− mice (f). Quantitative PCR analysis of indicated targets in the adipose tissue of
RD and HFD mice (g). Error bars in panels b, c and e indicate SEM. Ct, cycle threshold; Arbp, acidic ribosomal phosphoprotein P0
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The obese primary tumor microenvironment stimulates
the expansion of metastasis-initiating cells
Given the essential involvement of inflammation in
obesity [41], we next aimed at understanding how de-
creased angiogenesis and hypoxia modulate the immune
compartment in the primary tumor. FACS analyses re-
vealed that tumors from HFD mice contained 23% less
CD11b+F4/80+ macrophages (Additional file 4: Figure
S3A), which are mostly M1 macrophages in the C57BL/
6 model (Additional file 4: Figure S3B). In contrast, the
population of CD11b+F4/80− cells showed a 31% in-
crease in tumors from HFD mice. This population con-
sists of CD11b+Ly6CmedGr1+ neutrophils and
CD11b+Ly6Chigh monocytes (Fig. 4a). We confirmed
these results by performing western blot analyses and
found increased CD11b protein in tumor tissue lysates
from HFD mice, compared to tumors from RD mice
(Additional file 4: Figure S3C). Of note, this increase was
not seen in tumors grown in C57BL/6 Rag2−/− or FVB/
N mice fed with HFD diet (Additional file 4: Figure S3D
and E), which underscores again the immunological dif-
ferences between these strains. We then reasoned that if
fast-growing tumors in HFD-fed mice contain fewer M1
macrophages and more tumor associated neutrophils
(TANs) compared to tumors growing in RD-fed mice,
macrophage may be protective against tumor growth.
To test this hypothesis, we treated mice with clodro-
nate liposomes to deplete macrophages. Indeed, clo-
dronate liposome treatment boosted primary tumor
growth in HFD-fed mice (Fig. 4b) and did not reduce
metastasis (Additional file 4: Figure S3F). These re-
sults suggest that in our model, macrophages do not
Fig. 3 Increased tumor hypoxia in obese mice. Tumors in mice fed a high-fat diet (HFD) have higher Ki67+ counts (a, scalebar 200 um). CD31
immunohistochemical analysis shows lower vessel density in tumors from HFD mice (b, scalebar 200 uM). This is supported by fluorescence-
activated cell sorting quantification (c). Pimonidazole (PIMO) staining in mouse fed a regular diet (RD) or a HFD demonstrate greater hypoxic
areas in tumors from HFD mice (d, scalebar 200 uM). Quantitative PCR analyses on RD and HFD tumors show upregulation of hypoxia inducible
factor 1 alpha (HIF1α) targets (e, n = 5) and faster tumor progression (f, n = 5). Arbp, attachment region binding protein
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contribute to promote tumor progression and meta-
static spread, regardless of their essential involvement
in obesity.
In order to evaluate the importance of the effects of
the microenvironment on the tumor cells, we performed
cross-transplantation of tumor cells from HFD-fed and
RD-fed into RD-fed and HFD-fed mice, respectively.
Interestingly, we observed that tumor cells derived from
obese mice grew faster in lean recipient mice compared
to cells derived from lean mice (Fig. 4c). As expected,
grafting into obese mice further boosted growth of both
transplanted cell populations. These results uncoupled
immediate microenvironmental effects from tumor cell
effects and indicate that the obese tumor microenviron-
ment exerts contextual and sustained effects on tumor
cells.
Neutrophils are known to migrate to ischemic tissues
and to contribute to the epithelial-to-mesenchymal tran-
sition (EMT) [42]. EMT is a process involved in invasion
and metastasis and produces cancer stem cells (CSC)
[43], a subpopulation of cells that we and others have
previously shown to lead metastatic colonization [15].
Indeed, tumors from HFD mice consistently lost
E-cadherin and had an increase in N-cadherin and
vimentin, three hallmarks of EMT (Fig. 4d and
Additional file 5: Figure S4A). This effect was not
observed in FVB/N tumors (Additional file 5: Figure
S4B). In agreement with TANs being associated with
EMT, we identified strong correlation between the
expression of CD11b and N-cadherin and anti-
correlation with E-cadherin in primary tumors
(Additional file 5: Figure S4D).
All these assays were performed with equal-sized tu-
mors to avoid potential confounding effects due to more
rapid tumor growth in HFD-fed mice (Additional file 5:
Figure S4C). EMT is a distinctive feature of claudin-low
tumors, a particular subset of TNBC that is enriched in
CSC-related genes [44]. Since aggressive subtypes of
breast cancer such as TNBC and basal-like tumors are as-
sociated with mutations in p53 [23, 45–47], we next
Fig. 4 Microenvironmental effects on tumor cells. Tumors from mice fed a high-fat diet (HFD) contain greater numbers of neutrophils (a, n = 6
regular diet (RD), n = 14 HFD). Clodronate liposomes treatment increases tumor weight (b, n = 5 RD, n = 4 HFD). Cross-transplantation experiments
reveal that the effects of the obese microenvironment on tumor cells are permanent (c, n = 14). Immunofluorescent staining of tumors show
increased epithelial-mesenchymal transition (EMT) features in HFD groups (d). Tumor cells in tumors from mice fed RD or HFD injected intravenously
into RD mice show different metastasis initiating potential (e, n = 19). Clodro, clodronate liposomes; αSMA, alpha smooth muscle actin; l, lean; O, obese
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stained for p53, a surrogate marker for its mutational sta-
tus. Our results indicate that tumors in obese mice have a
higher number of p53-positive cells (Additional file 5:
Figure S4E). As a consequence, they also show
significantly lower levels of p21(WAF1/CIP1), an im-
portant target of p53 responsible for cell cycle arrest
(Additional file 5: Figure S4A).
Claudin-low tumors are also characterized by a loss of
cell-cell junction proteins. Therefore, we next performed
qPCR analyses in tumors from RD and HFD mice using
a number of genes from the cell-cell junction
organization gene set M820 from the MSigDB database
[48], as previously described [23]. The results confirmed
that the obese microenvironment triggers a process that
leads to the rapid expansion of claudin-low tumors
(Additional file 5: Figure S4F).
Finally, to test whether the effects of obesity on the pri-
mary tumor are essential for the late steps of cancer me-
tastasis, we digested tumors from RD and HFD mice and
injected 5 × 105 tumor cells via the tail vein into
tumor-free, RD mice. Our results demonstrate that tumor
cells derived from obese mice metastasize more to the
lungs compared to cells derived from lean mice (Fig. 4e),
i.e. tumors from obese mice contain more CSC with
metastasis-initiating capacity. Our data provide direct
evidence that the primary tumor microenvironment of
obese mice generates more tumor cells with lung
metastasis-initiating capacity.
Discussion
To date, the link between obesity and worse outcomes
observed in patients with breast cancer remains poorly
understood, mainly due to the lack of experimental stud-
ies based on mouse models of metastasis that explore
the full metastatic cascade. In this study, we used ortho-
topic, syngeneic models of spontaneous breast cancer
metastasis and have discovered a novel experimental link
between obesity and tumor progression to metastasis;
collectively, our results show that the interactions be-
tween hypoxia, elements of the tumor microenviron-
ment (likely neutrophils) and tumor cells ultimately
orchestrate a shift towards TNBC/claudin-low tumors
and a consequent increase in metastasis-initiating cells
within primary tumors in obese mice. Overall, our data
provide an experimental link with clinical observations
describing higher TNBC rates in obese patients [2, 49].
Moreover, premenopausal and postmenopausal, over-
weight and obese patients with breast cancer are gener-
ally at higher risk of recurrence and resistance to
therapy [1, 2, 12, 50–52]. Biganzoli and collaborators
used data from the prospective “three-arms” trial with
very long follow up to show that the patient’s BMI at
diagnosis is associated with specific recurrence patterns
over time [53]. They observed for example that obese
patients present with at least two peaks of recurrences,
one early and one late. Our results showing TNBC fea-
tures and increased CSC content in tumors in obese
mice might explain the higher risk of recurrence and re-
sistance to therapy observed in overweight and obese
humans, although this hypothesis requires further stud-
ies to be confirmed.
Interestingly, recent work suggests that higher neutro-
phil infiltration in the lungs of obese mice results in
higher metastatic burden [13]. While in our setting pri-
mary tumor hypoxia could also be responsible for the
generation of a neutrophilic premetastatic niche in the
lungs [54], we here showed that the events in the pri-
mary tumor promote increased metastasis in obese mice
without the need for preconditioning the distant meta-
static site. Accordingly, in secondary transplants obese
primary tumors have higher metastatic potential regard-
less of the host in which they are grafted. The different
conclusions between this work [13] and ours are likely
to be explained by experimental differences, the most
significant of which is the use of orthotopic models of
spontaneous lung metastasis, which is the only strategy
that allows study of the whole metastatic cascade. In
addition, our obese mice were ovariectomized, thereby
better mimicking postmenopausal obesity in patients. In
short, while our results do not exclude additional metas-
tasis-promoting effects in the secondary site, they clearly
reveal important effects of postmenopausal obesity on the
primary tumor which are critical for metastatic spread
and colonization. We therefore think that our model pro-
vides a more clinically relevant approach to unravel the ef-
fects of obesity on breast cancer progression.
Due to the lack of ovarian-derived estrogens, postmeno-
pausal women are more prone to increases in their BMI.
We show that in our model this is not due to dietary fac-
tors but, similarly to humans, it is linked to each individ-
ual’s susceptibility to become obese [26]. Indeed, to
address the importance of the diet in the progression of
breast cancer, we used obesity-resistant M2/Th2 FVB/N
mice and demonstrated that the diet alone, i.e. in the ab-
sence of obesity, is not sufficient to affect tumor growth.
Local estrogen production has also been linked to the
increased risk of breast cancer and contributes to pro-
gression in postmenopausal women, given that after
menopause the production of estrogens is thought to
occur mainly in the adipose tissue [55]. However, we
were not able to detect aromatase transcripts in the adi-
pose tissue or the tumors of RD or HFD mice (data not
shown), which rules out potential effects of local estro-
gen production on tumor growth in obese animals.
Obesity is characterized by low-grade chronic inflamma-
tion. Our results indicate correlation between the infiltra-
tion of neutrophils in the primary tumor and the
acquisition of a more mesenchymal phenotype by tumor
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cells. In contrast, Kolb and collaborators found that the
inflammasome of macrophages in primary tumors in
obese mice is responsible for triggering angiogenesis
through expression of vascular endothelial growth factor
A (VEGFA), consequently boosting primary tumor growth
[10]. Our results differ in that we did not see increased
macrophage content in tumors from obese mice, and we
observed a reduction in vessel density with a concomitant
increase in hypoxia. We argue that this decrease in
vascularization is the same as observed in the adipose tis-
sue during obesity [56], and we suggest that higher prolif-
erative rates may be the result of p53 dysregulation.
Notwithstanding the differences between Kolb et al. and
our group, it is worth noting that in our experimental set-
ting elimination of macrophages by treatment with clo-
dronate liposomes did not reduce tumor growth but
rather the opposite. In addition, we and others have ob-
served that clodronate treatment reduces body weight in
obese mice, which is consistent with an obesity-promoting
effect of M1 macrophages [57]. Finally, it is known that
during obesity there is an increase in neutrophil recruit-
ment in the adipose tissue, which mediates insulin
resistance [58, 59]. Overall, our results indicate that
obesity-associated macrophages play a crucial role in
stimulating the growth of the adipose tissue, but they have
antagonistic effects on cancer progression. We here sug-
gest that other immune cells, such as neutrophils, might
be involved in primary tumor progression in obesity. Our
model might prove useful in identifying further key factors
relevant to breast cancer progression in obesity and to
evaluate potential therapeutic strategies.
Conclusions
In summary, we have found that decreased vascularization
in the primary tumors of postmenopausal obese mice trig-
gers hypoxia, neutrophil infiltration and EMT, leading to
the expansion of TNBC/claudin-low tumors and an in-
crease in metastasis-initiating cells. These results provide
an explanation for the higher incidence of metastasis and
higher ratio of TNBC observed in obese patients with
breast cancer and challenge the recent notion that
tumor-cell extrinsic factors in the secondary site are clin-
ically relevant to these patients.
Additional files
Additional file 1: Table S1. (DOCX 45.3 kb)
Additional file 2: Figure S1. Scheme of the experimental procedure
(A). Body weight comparison between ovariectomized (n = 12 RD, n = 12
HFD) and non-ovariectomized (n = 5 RD, n = 5 HFD) mice (B). Body
weight of ovariectomized RD and HFD mouse groups after 13 weeks of
diet (C; n = 29 RD and n = 35 HFD). Data distribution of mouse weight in
RD (D) and HFD (E) groups. Number of metastases seeded by same-sized
tumors in RD and HFD mice (F and G). Error bars in panel B indicate SEM.
(TIF 2261 kb)
Additional file 3: Figure S2. CD31 staining in C57BL/6 Rag2−/− mice
show no differences between tumors from RD and HFD mice when they
are grown in C57BL/6 Rag2−/− hosts (A, scalebar = 100uM). HIF1a staining
in wild-type (wt) and C57BL/6 Rag2−/− mice show that hypoxia is increased
in tumors from wt obese mice, while it is not changed in tumors in HFD-
fed C57BL/6 Rag2−/− mice (B, scalebar 100 uM). HE staining of RD and HFD
tumors showing enlarged nuclei and less packed chromatin in the latter (C,
scalebar 50 um). IHC analyses in tumor samples show faster progression in
HFD compared to RD tumors (D, n = 5, scalebar 50 um). (JPG 3325 kb)
Additional file 4: Figure S3. FACS analyses show lower percentages of
F4/80+ macrophages in the CD11b + compartment in Py230 HFD tumors
(A, n = 18 RD, n = 20 HFD). Percentages of M1 (F4/80 + CD206-) and M2
macrophages (F4/80 + CD206+) identified in the CD11b + compartment of
C57BL/6 and FVB/N mice (B, n = 3 RD, n= 7 HFD for C57BL/6 and n = 4 RD,
n= 4 HFD for FVB/N). Normalized western blot analysis for CD11b in
Py230-C57BL6 tumors (C; N= 8), Py230-C57BL/6;Rag2−/− tumors (D; N= 9)
and PyMT-FVB/N tumors (E; n = 8). Clodronate liposomes treatment increases
metastasis (F, n= 5 RD, n= 6 HFD). (TIF 1676 kb)
Additional file 5: Figure S4. Western blot analysis for E-cadherin, N-
cadherin, p21, and HIF1a in Py230-C57BL/6 tumor lysates of RD and HFD
(A). Western blot analysis for E-cadherin in PyMT tumors grown in FVB/N
mice (B). Tumor weight of groups used for qPCR and western blot
analyses (C, N = 10). CD11b strongly correlates with N-cadherin and
anti-correlates with E-cadherin (D, N = 10). IHC on RD vs HFD tumors
show nuclear p53 accumulation in the latter (E, scalebar 100 uM). qPCR
analyses on Py230 RD and HFD tumors show significant downregulation
of claudins and other cell-cell junction genes (F, n = 5). (TIF 9127 kb)
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